The locally produced vaccine will aid China’s efforts in polio eradication. Rebecca Tan | February 5, 2015 | Top News
AsianScientist (Feb. 5, 2015) - The China Food and Drug Administration (CFDA) has approved the production of the first locally-developed inactivated poliomyelitis vaccine. It is the first vaccine to be made from inactivated Sabin strains. Polio is a virus-transmitted disease that can lead to paralysis and limb deformation. Two effective vaccines currently exist, the inactivated or Salk vaccine and the attenuated or Sabin vaccine. The Salk vaccine is made from viruses that have been killed or inactivated by formaldehyde and therefore carries no risk of vaccine-induced polio.
The Sabin vaccine, on the other hand, is a live but attenuated (weakened) virus that is administered orally. Although there is a small chance of the attenuated virus causing paralysis (one in 2.7 million), the Sabin vaccine confers long lasting protection and prevents the spread of the virus by reducing intestinal shedding. The inactivated Sabin vaccine was developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences. The vaccine will be administered by injection and is intended for use in children. By locally manufacturing the vaccine rather than relying on expensive imports, it is hoped that China will be able to meet the demand of several million doses a year. ——
Source: China Food and Drug Administration; Photo: Shutterstock. Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff. Read more from Asian Scientist Magazine at: http://www.asianscientist.com/2015/02/topnews/cfda-approves-inactivated-sabin-vaccine/
Post Polio Litaff, Association A.C _APPLAC Mexico